Patents Issued in June 4, 2019
  • Patent number: 10307447
    Abstract: A process includes reducing one or more pieces of cannabis plant matter to a powder by freeze-drying the one or more pieces of cannabis plant matter, and then extracting one or more chemicals from the powder by pressurizing the powder in a pressure vessel with along with liquid or supercritical carbon dioxide. The carbon dioxide dissolves the one or more chemicals. The powder is then depressurized to precipitate the one or more chemicals out of the carbon dioxide, and the precipitated chemicals can then be collected. For example, the freeze-drying ruptures the plant cells in the cannabis plant matter, thereby exposing or releasing the chemicals in the plant cells.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: June 4, 2019
    Inventor: Stephen Goldner
  • Patent number: 10307448
    Abstract: The invention discloses a method for manufacturing an extract of Rhinacanthus nasutus (L.) Kurz in order to obtain the extract of Rhinacanthus nasutus (L.) Kurz with improved contents of active ingredients, wherein the method comprising the steps of: soaking a raw sample of Rhinacanthus nasutus (L.) Kurz with a processing reagent at 22 to 37° C. for 12 to 36 hours; boiling the soaked product at 1 atm, 95 to 105° C. for 15 minutes to 1 hour to obtain the processed sample of Rhinacanthus nasutus (L.) Kurz; extracting the processed sample of Rhinacanthus nasutus (L.) Kurz by 95% ethanol at 50° C.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: June 4, 2019
    Assignee: HAN SHENG BIOTECH CO., LTD.
    Inventors: Shorong-Shii Liou, I-Min Liu, Chia-Ju Chang, Hou-Ru Ciou, Wei-Fan Chou
  • Patent number: 10307449
    Abstract: Compositions and formulations comprising polymeric myrcene. More particularly, the invention relates to compositions comprising an isolated fraction of polymeric myrcene in a hydrophobic carrier and formulations which maintain the biological activity of the active polymer.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: June 4, 2019
    Assignee: REGENERA PHARMA LTD.
    Inventors: Zadik Hazan, Shimon Amselem
  • Patent number: 10307450
    Abstract: A method of treating neurological condition in a subject by administration of a neuroprotective composition of a mixture of two or more triterpenes. Alzheimer's disease, Huntington's disease, stroke or Parkinson's disease are treated by administering a therapeutically effective amount of the neuroprotective composition to a subject.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: June 4, 2019
    Assignee: Phoenix Biotechnology, Inc.
    Inventors: Otis C. Addington, Robert A. Newman
  • Patent number: 10307451
    Abstract: The present invention provides compositions comprising optimized ratios of Red clover phytoestrogens as determined by a proprietary physiologically based pharmacokinetic and pharmacodynamic model. The compositions are useful for modulating, preventing or treating postmenopausal or climacteric symptoms, which include but are not limited to bone loss, bone remodeling, hot flushes and vaginal atrophy. The present invention also provides methods for modulating, preventing or treating postmenopausal or climacteric symptoms using the compositions disclosed herein.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: June 4, 2019
    Assignee: SINOVEDA CANADA INC.
    Inventors: Yun Kau Tam, Yi-Chan James Lin, Brian Duff Sloley, Chih-Yuan Tseng
  • Patent number: 10307452
    Abstract: A method of reducing the number of microorganisms entering the nose and proliferating in the nasal cavity including application of a solution of an antimicrobial, antiviral and antifungal composition to the anterior vestibular region of the nares. The antimicrobial, antiviral and antifungal solution includes ethyl alcohol as an active ingredient. Various embodiments may also include one or more of the following additional ingredients: orange oil; lemon oil; grapefruit oil; tangerine oil; mandarin oil; lime oil; bergamot oil; petitgrain essential oil; and other citrus oils; meadowfoam seed oil; soy oil; emu oil; grapefruit seed extract; glycine soja; simmondsia chinensis (Jojoba); lauric acid; chlorhexidine gluconate; ginger oil; lavender oil; peppermint oil; spearmint oil; aloe oil; one or more terpenes and/or terpenoids; and a preservative, such as benzalkonium chloride and vitamin E.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: June 4, 2019
    Assignee: GLOBAL LIFE TECHNOLOGIES CORP.
    Inventor: John A. Willimann
  • Patent number: 10307453
    Abstract: A method for extracting stilbene compounds comprises the following steps: grinding a medicinal material rich in stilbene compounds such as rheum officinale; extracting the medicinal material with a herbal flash extractor for one to four times, 5-20 minutes each time; filtering and combining filtrate and concentrating the filtrate to dryness; the proportion of the medicinal material to a solvent being 1 g: 10 ml-1 g:15 ml.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: June 4, 2019
    Assignee: KPC PHARMACEUTICALS, INC
    Inventors: Yunqi Gong, Jinxin Chen, Fang Fang
  • Patent number: 10307454
    Abstract: Composition and methods for treating brain “plaques” and “tangles” in a patient or an animal wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract and an oolong tea extract.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: June 4, 2019
    Assignee: Cognitive Clarity Inc.
    Inventors: Judy Cam, Thomas Lake, Qubai Hu, Joel Cummings, Alan D. Snow
  • Patent number: 10307455
    Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 4, 2019
    Assignees: Acceleron Pharma Inc., Adimab, LLC
    Inventors: Ravindra Kumar, Jonathan Belk, Asya Grinberg, Dianne Sako, Roselyne Castonguay
  • Patent number: 10307456
    Abstract: Disclosed herein are synthetic peptides and compositions comprising the same for the treatment and/or prophylaxis of an ocular disease, particularly, dry eye disease. Also disclosed herein are methods of treating and/or preventing an ocular disease by administering to a subject in need of such treatment a composition containing a synthetic peptide of the present disclosure.
    Type: Grant
    Filed: February 25, 2015
    Date of Patent: June 4, 2019
    Assignee: MACKAY MEMORIAL HOSPITAL
    Inventors: Tsung-Chuan Ho, Yeou-Ping Tsao
  • Patent number: 10307457
    Abstract: New improved formulations are described, comprising at least a first composition, with or without a second composition, in which the first composition is an inhibitor of lipid A deacetylase resulting in permeabilization of an outer membrane of a susceptible microorganism to which it is provided to. The second composition is a streptogramin. Said first composition, alone or in combination, may be used to improve and/or treat a wide variety of bacterial infections, providing better efficacy, bioavailability, and/or pharmacokinetics, as compared with at least other inhibitors of lipid A deacetylase. When provided to a susceptible microorganism as a combination of the first composition and the second composition, the combination may be provided independently or may be provided together (co-combined in a same formulation, or in different formulations).
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: June 4, 2019
    Assignee: FLEURIR ABX LLC
    Inventor: John Lee Pace
  • Patent number: 10307458
    Abstract: As described herein, an peptide of SEQ ID NO: 1 is modified at the terminal end. Specifically, the carboxyl-group of the leucine at the terminal end of the amino acid sequence FCIGRL (SEQ ID NO: 1) is modified with a —CONH2. This modified peptide is used as a permeation enhancer to boost the mucous membrane permeation, thereby noticeably increasing the bioavailability of a drug that is administered together with the modified peptide. The drug to be administered with the modified peptide can be cyclosporine A.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: June 4, 2019
    Assignee: Soonchunhyang University Industry Academy Cooperation Foundation
    Inventor: Keon-Hyoung Song
  • Patent number: 10307459
    Abstract: Good bioavailability of desmopressin can be obtained with an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 4, 2019
    Assignee: FERRING B.V.
    Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
  • Patent number: 10307460
    Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: June 4, 2019
    Assignee: Allegro Pharmaceuticals, LLC
    Inventors: Michael John Mackel, John Park
  • Patent number: 10307461
    Abstract: Disclosed is a method of treating or preventing polycystic kidney disease (PKD) by administration of neutrophil geleatinase-associated lipocalin (Ngal) protein. Also, a transgenic non-human animal model is established to investigate the effect of overexpression of exogenous Ngal on PKD progression.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 4, 2019
    Assignee: NATIONAL TAIWAN NORMAL UNIVERSITY
    Inventors: Hsiu-Mei Hsieh, Yi-Ren Wang, Si-Tse Jiang, Wen-Yih Jeng, Yuan-Yow Chiou
  • Patent number: 10307462
    Abstract: Methods of inducing thrombopoiesis and/or treating thrombocytopenia in a subject are provided. Accordingly there is provided a method comprising contacting stem cells with a differentiation potential towards platelets or hematopoietic progenitor cells derived therefrom with Livin, thereby inducing thrombopoiesis. Also provided is a method comprising contacting cells with a differentiation potential towards platelets with tLivin, thereby inducing thrombopoiesis. Also provided are compositions and isolated population of cells for inducing thrombopoiesis and/or treating thrombocytopenia in a subject.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: June 4, 2019
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Dina Ben Yehuda, Ihab Abd-Elrahman, Riki Perlman, Marjorie Pick
  • Patent number: 10307463
    Abstract: The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: June 4, 2019
    Assignee: TerSera Therapeutics LLC
    Inventors: David J. Ellis, George P. Miljanich, David E. Shields
  • Patent number: 10307464
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: June 4, 2019
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Richard Petrucci
  • Patent number: 10307465
    Abstract: Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 4, 2019
    Assignee: Tyme, Inc.
    Inventor: Steven Hoffman
  • Patent number: 10307466
    Abstract: The present invention provides an orally administered composition comprising a sophorolipid, a physiologically active substance, and an oil or fat, wherein the physiologically active substance exhibits an improved bioavailability.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: June 4, 2019
    Assignee: SARAYA CO., LTD.
    Inventors: Yasushi Suzuki, Hiromitsu Tabata, Mizuyuki Ryu, Nanase Ishii, Takashi Takeuchi, Yasuki Matsumura, Kentaro Matsumiya
  • Patent number: 10307467
    Abstract: Provided are methods and kits for reducing the severity of muscle stiffness. The method comprises delivering to one or more specific locations in the deep fascia of an affected muscle a composition comprising a therapeutically effective amount of hyaluronidase.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: June 4, 2019
    Assignee: New York University
    Inventors: Preeti Raghavan, Antonio Stecco
  • Patent number: 10307468
    Abstract: Methods for producing di-chain BoNT/A from single chain BoNT/A using Lys-C followed by purification using a hydrophobic surface.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: June 4, 2019
    Assignee: IPSEN BIOINNOVATION LIMITED
    Inventors: Shilpa Palan, Sai Man Liu, Gavin Stephen Hackett
  • Patent number: 10307469
    Abstract: Synthetic polynucleotides encoding human methylmalonyl-CoA mutase (synMUT) and exhibiting augmented expression in cell culture and/or in a subject are described herein. An adeno-associated viral (AAV) gene therapy vector encoding synMUT under the control of a liver-specific promoter (AAV2/8-HCR-hAAT-synMUT-RBG) successfully rescued the neonatal lethal phenotype displayed by methylmalonyl-CoA mutase-deficient mice, lowered circulating methylmalonic acid levels in the treated animals, and resulted in prolonged hepatic expression of the product of synMUT transgene in vivo, human methylmalonyl-CoA mutase (MUT).
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: June 4, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Charles P. Venditti, Randy J. Chandler
  • Patent number: 10307470
    Abstract: Immunogenic compositions, cancer vaccines and methods for treating cancer comprising FMS, the fucose-enriched polysaccharide fraction from Reishi F3, are provided. Compositions comprise fucose-enriched Reishi polysaccharide fraction (FMS) MW=˜35 kDa, wherein the FMS is isolated by size-exclusion chromatography from Reishi F3, and the FMS comprises polysaccharides having primarily a backbone selected from 1,4-mannan and 1,6-?-galactan, wherein the backbone is linked to a terminal fucose-containing side-chain Immunogenic compositions comprising glycolipid adjuvants are provided. Antibodies generated by immunogenic compositions disclosed herein bind cancer cells comprising antigens Globo H, Globo H, Gb3, Gb4, Gb5 (SSEA-3) and SSEA-4 on the cell surface.
    Type: Grant
    Filed: July 26, 2014
    Date of Patent: June 4, 2019
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Hsien-Yeh Hsu, Shih-Fen Liao, Chi-Hui Liang
  • Patent number: 10307471
    Abstract: The present invention provides an immunity inducer and an immunity inducing method using same. The immunity inducer has an immunopotentiation effect on any target oligosaccharide antigen, in particular oligosaccharide antigens included in mammal-derived glycoprotein N-linked sugar chains; is capable of providing a monoclonal antibody having high specificity to and affinity with target oligosaccharide antigens; and has as an effective component thereof a glycolipid including a target oligosaccharide antigen (R) and indicated by general formula (2), or a salt thereof. General formula (2): R—Z—Y—CH(NH—CO—(CH2)n1—CH3)—CH2)n2—CH3 (in the formula, R indicates a straight-chain or branched oligosaccharide comprising 2-30 of at least one type of monosaccharide. Z indicates a single bond, O, S or NH, a linker bound to thiomethyl, amino methylated sugar alcohol. Y indicates —(CH2)m—. n1 indicates an integer of 2-40, n2 indicates an integer of 1-27, and m indicates an integer of 1-30).
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: June 4, 2019
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Tetsuya Okuda, Hiroki Shimizu
  • Patent number: 10307472
    Abstract: The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 4, 2019
    Assignee: CureVac AG
    Inventors: Mariola Fotin-Mleczek, Karl-Josef Kallen, Jan C. Schmollinger
  • Patent number: 10307473
    Abstract: The present invention encompasses a novel S. aureus bioconjugate vaccine. More generally, the invention is directed to Gram-positive and other bioconjugate vaccines containing a protein carrier, at least one polysaccharide such as a capsular Gram-positive polysaccharide, and, optionally, an adjuvant or pharmaceutically acceptable carrier. The instant invention also includes methods of producing Gram-positive and other bioconjugate vaccines. An N-glycosylated protein is also provided that contains one or more polysaccharides such as Gram-positive polysaccharides. The invention is additionally directed to engineered prokaryotic organisms comprising nucleotide sequences encoding a glycosyltransferase of a first prokaryotic organism and a glycosyltransferase of a second prokaryotic organism. The invention further includes plasmids and prokaryotic cells transformed with plasmids encoding polysaccharides and enzymes which produce an N-glycosylated protein and/or bioconjugate vaccine.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: June 4, 2019
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Michael Wacker, Michael Kowarik, Michael Wetter
  • Patent number: 10307474
    Abstract: Provided herein are host cells capable of producing hybrid oligosaccharides and polysaccharides, wherein said hybrid oligosaccharides and polysaccharides do not comprise a hexose at the reducing end of their first repeat unit. Also provided herein are hybrid oligosaccharides or polysaccharides and bioconjugates which can be produced by the host cells described herein, wherein said bioconjugates comprise a carrier protein linked to a hybrid oligosaccharide or polysaccharide that does not comprise a hexose at the reducing end of its first repeat unit.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: June 4, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventor: Amirreza Faridmoayer
  • Patent number: 10307475
    Abstract: Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: June 4, 2019
    Assignee: Academia Sinica
    Inventors: Chi-Huey Wong, Che Ma, Cheng-Chi Wang, Juine-Ruey Chen
  • Patent number: 10307476
    Abstract: Provided herein are recombinant respiratory syncytial viruses that contain mutations that make the disclosed viruses attractive vaccine candidates. The viruses disclosed contain attenuating mutations designed to have increased genetic and phenotypic stability. Desired combinations of these mutations can be made to achieve desired levels of attenation. Exemplary vaccine candidates are described. Also provided are polynucleotides capable of encoding the described viruses, as wells as methods for producing the viruses and methods of use.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 4, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Cindy L. Luongo, Ursula J. Buchholz, Brian R. Murphy
  • Patent number: 10307477
    Abstract: Methods for inducing an immune response against Human Immunodeficiency Virus (HIV) in HIV-infected subjects undergoing antiretroviral therapy (ART) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (MVA) vector booster vaccine encoding mosaic HIV antigens.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: June 4, 2019
    Assignees: Janssen Vaccines & Prevention B.V., The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Beth Israel Deaconess Medical Center, Inc., The United States of America, as represented by The Secretary Of The Army
    Inventors: Frank Tomaka, Maria Grazia Pau, Johanna Schuitemaker, Dan Barouch, Jintanat Ananworanich, Merlin Robb, Nelson L. Michael, Jerome Kim
  • Patent number: 10307478
    Abstract: Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: June 4, 2019
    Assignees: Beth Israel Deaconess Medical Center, Inc., Children's Medical Center Corporation
    Inventors: Stephen C. Harrison, Bing Chen, Dan H. Barouch, Joseph P. Nkolola, Michael Scott Seaman
  • Patent number: 10307479
    Abstract: This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: June 4, 2019
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventor: Nai-Kong V. Cheung
  • Patent number: 10307480
    Abstract: Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: June 4, 2019
    Assignee: Scholar Rock, Inc.
    Inventors: Michelle Straub, Dong Yun Lee, William K. McConaughy, Katherine Jane Turner, Nagesh K. Mahanthappa, Justin W. Jackson
  • Patent number: 10307481
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Grant
    Filed: July 25, 2006
    Date of Patent: June 4, 2019
    Assignee: Aptevo Research and Development LLC
    Inventors: Laura S. Grosmaire, Martha S. Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter A. Thompson, Sandy A. Simon, William Brady
  • Patent number: 10307482
    Abstract: Described are nanoparticle complexes comprising paclitaxel, albumin and anti-EGFR antibodies. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses EGFR.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: June 4, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10307483
    Abstract: The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 4, 2019
    Assignee: AMGEN INC.
    Inventors: Monica Goss, Nicole Ball
  • Patent number: 10307484
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the NSAID for the treatment of conditions such as pain.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: June 4, 2019
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 10307485
    Abstract: A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 4, 2019
    Assignee: Wyeth LLC
    Inventors: David Hugh Giamalva, Gary Bruce Anderson
  • Patent number: 10307486
    Abstract: The present disclosure relates to surface modified nanocrystalline cellulose (NCC) prepared by chemical modification of NCC as well as its use thereof, including as carrier of particular chemical compounds. The surface of nanocrystalline cellulose (NCC) was modified with chitosan oligosaccharide (CSOS) by selectively oxidizing the primary alcohol moieties of NCC followed by coupling of the amino groups of CSOS to the oxidized NCC to provide the desired material (NCC-CSOS).
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 4, 2019
    Assignee: Celluforce Inc.
    Inventors: Seyedeh Parinaz Akhlaghi, Kam Chiu Tam, Richard M. Berry
  • Patent number: 10307487
    Abstract: Disclosed herein are microvessel endothelial cell surface markers and methods, compositions, agents, and kits relating to those surface markers.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: June 4, 2019
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital
    Inventors: Ulrich H. von Andrian, Aude Thiriot, Omid Farokhzad, Jinjun Shi
  • Patent number: 10307488
    Abstract: Disclosed are novel antibody-drug conjugates and use thereof in therapy, in particular in anticancer or anti-inflammatory therapy, as well as synthetic products useful as linkers, composed of a linker head and a linker body, and also a method for preparing the linkers and the antibody-drug conjugates.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: June 4, 2019
    Assignee: UNIVERSITE FRANCOIS RABELAIS
    Inventors: Nicolas Joubert, Marie Claude Viaud-Massuard, Renaud Respaud
  • Patent number: 10307489
    Abstract: A dye-drug conjugate for preventing, treating, or imaging cancer having the following structure: wherein R1 and R2 are independently selected from the group consisting of —H, alkyl, alkyl-sulphonate, alkylcarboxylic, alkylamino, aryl, —SO3H, —PO3H, —OH, —NH2, and -halogen; wherein Y1 and Y2 is independently selected from the group consisting of alkyl, aryl, aralkyl, alkylsulphonate, alkylcarboxylic, alkylamino, ?-alkylaminium, ?-alkynyl, PEGyl, PEGylcarboxylate, ?-PEGylaminium, ?-acyl-NH, ?-acyl-lysinyl-, ?-acyl-triazole, ?-PEGylcarboxyl-NH—, ?-PEGylcarboxyl-lysinyl, and ?-PEGylcarboxyl-triazole; wherein X is selected from the group consisting of a hydrogen, halogen, CN, Me, NH2, SH and OH; and R3 and R4 are independently a hydrogen, a therapeutic agent, or an imaging moiety, wherein the therapeutic agent is selected from the group consisting of a platinum-based therapeutic agent, a small molecule therapeutic agent, a peptide, a protein, a polymer, an siRNA, a microRNA, and a nanoparticle, wherein the ima
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: June 4, 2019
    Inventor: Leland W. K. Chung
  • Patent number: 10307490
    Abstract: Described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a targeting agent. The composition can include a therapeutic agent. The therapeutic agent can be an antisense oligonucleotide (ASO). Exemplary ASOs are targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1; or targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Also described is a lipid nanoparticle composition that includes a macromolecule conjugated to a polymer and a therapeutic agent that is an ASO such as an ASO targeted to a portion of a nucleic acid encoding Akt-1, and which modulates the expression of Akt-1 or an ASO targeted to a portion of a nucleic acid encoding HIF-1, and which modulates the expression of HIF-1. Pharmaceutical formulations, methods of making the lipid nanoparticles, and methods of using the lipid nanoparticles, for example for treating cancers, are also disclosed.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: June 4, 2019
    Assignee: The Ohio State University
    Inventors: Robert J. Lee, Young Bok Lee, Deog Joong Kim, Chang Ho Ahn
  • Patent number: 10307491
    Abstract: Provided herein are liposomal particles. In particular, provided herein are liposomal particles comprising molecules (e.g., antigens or drugs) and uses thereof (e.g., as a vaccine (e.g., intranasal vaccine) or drug delivery system). For example, in some embodiments, the present disclosure provides a composition comprising: a molecule encapsulated in a liposome comprising one or more cationic lipids and hyaluronic acid (HA). In some embodiments, the one or more lipids are DOTAP and/or DOPE. In some embodiments, the HA is thiolated. In some embodiments, the thiolated HA is conjugated to thiolated PEG.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: June 4, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: James Jaehyun Moon, Yuchen Fan, Preety Sahdev, Joseph Bazzill
  • Patent number: 10307492
    Abstract: The invention provides nucleic acids and nucleic acid expression vectors containing optimized mGluR6 promoters for expression of transgenes in the retina. The compositions and methods of the invention are useful for expression of gene products to preserve, improve, or restore phototransduction or vision.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: June 4, 2019
    Assignee: Wayne State University
    Inventors: Zhuo-Hua Pan, Qi Lu, Tushar H. Ganjawala, JrGang Cheng
  • Patent number: 10307493
    Abstract: This invention concerns imageable, radiopaque embolic beads, which are particularly useful for monitoring embolization procedures. The beads comprise iodine containing compounds which are covalently incorporated into the polymer network of a preformed hydrogel bead. The beads are prepared by activating pre-formed hydrogel beads towards nucleophilic attack and then covalently attaching iodinated compounds into the polymer network. The radiopaque beads may be loaded with chemotherapeutic agents and used in methods of embolizing hyperplastic tissue or solid tumors.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 4, 2019
    Assignees: Biocompatible UK Limited, National Institutes of Health
    Inventors: Matthew R. Dreher, Bradford J. Wood, Ayele H. Negussie, Andrew Leonard Lewis, Yiqing Tang
  • Patent number: 10307494
    Abstract: A biocompatible curable composition and a method of detecting a border of a tumor, a tissue of interest, or both including injecting the biocompatible curable composition and contacting the border of a tumor or a tissue, the biocompatible curable composition crosslinks to form a three-dimensional cured nanocomposite, and imaging the three-dimensional (3D) cured nanocomposite, and imaging the 3D cured nanocomposite by at least one of MRI, CT, ultrasound, and X-ray, to detect the border of the tumor or the tissue of interest or track tumor motion during radiotherapy treatment. The biocompatible curable composition comprising an organic polymer having a hydrolysable functional group, a metallic nanoparticle, and a polar or a non-polar solvent. A brachytherapy strand consisting of a biocompatible curable composition and a radio-isotope seed. The biocompatible curable composition is shaped into an elongated cylinder and forms a 3D cured nanocomposite with a radio-isotope seed embedded.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: June 4, 2019
    Assignees: National Guard Health Affairs, King Saud bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center
    Inventor: Mamdooh Alqathami
  • Patent number: 10307495
    Abstract: A sterilizing apparatus having both excellent safety and operability is provided. A sterilizing apparatus (1) according to an aspect for carrying out the present invention is a sterilizing apparatus (1) that radiates light including ultraviolet rays onto an affected area (6), wherein first wavelength light (L?1) having a peak wavelength in a wavelength range of 190 nm or more and 230 nm or less, and second wavelength light (L?2) having a peak wavelength in a wavelength range of 400 nm or more and 780 nm or less are emitted.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: June 4, 2019
    Assignee: SHARP KABUSHIKI KAISHA
    Inventors: Jun Mori, Tim Michael Smeeton
  • Patent number: 10307496
    Abstract: Sterilization method according to which an aqueous polysaccharide solution is stored in the presence of a lactone and a buffer system for a period of at least 24 hours, and a sterile polysaccharide solution produced in this way.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: June 4, 2019
    Assignee: HERAEUS MEDICAL GMBH
    Inventors: Sebastian Vogt, Thomas Kluge